Deletion of Cbl-b inhibits CD8(+) T-cell exhaustion and promotes CAR T-cell function

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy is an emerging option for cancer treatment, but its efficacy is limited, especially in solid tumors. This is partly because the CAR T cells become dysfunctional and exhausted in the tumor microenvironment. However, the key pathways responsib...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Jitendra, Kumar, Ritesh, Kumar Singh, Amir, Tsakem, Elviche L, Kathania, Mahesh, Riese, Matthew J, Theiss, Arianne L, Davila, Marco L, Venuprasad, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813298/
https://www.ncbi.nlm.nih.gov/pubmed/33462140
http://dx.doi.org/10.1136/jitc-2020-001688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813298/
https://www.ncbi.nlm.nih.gov/pubmed/33462140
http://dx.doi.org/10.1136/jitc-2020-001688

Ejemplares similares